Bausch Health Companies (NYSE: BHC) insider transactions
In the twelve months to 10 November 2026, executives and directors of Bausch Health Companies reported 5 open-market sales of 80,947 shares ($506,730) and 1 open-market purchase of 2,500,000 shares ($15.6m), by 4 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 30 September 2026 | Wechsler Amy B | Director | Grant or award | +1,179 | $5.83 | 316,158 | Form 4 |
| 30 September 2026 | Leung Sandra | Director | Grant or award | +5,789 | $5.83 | 102,859 | Form 4 |
| 30 September 2026 | Paulson John | Director | Grant or award | +10,720 | $5.83 | 440,962 | Form 4 |
| 19 August 2026 | Lenar Aimee J. | President, US Pharma | Open-market sale, 10b5-1 plan | −36,827 | $7.03 | 334,853 | Form 4 |
| 17 July 2026 | Lenar Aimee J. | President, US Pharma | Shares withheld for tax | −5,260 | $4.83 | 371,680 | Form 4 |
| 15 July 2026 | Lenar Aimee J. | President, US Pharma | Shares withheld for tax | −23,395 | $4.89 | 376,940 | Form 4 |
| 14 July 2026 | Lee Steven Hyosig | SVP, Controller & CAO | Shares withheld for tax | −3,125 | $4.75 | 70,114 | Form 4 |
| 30 June 2026 | Leung Sandra | Director | Grant or award | +6,845 | $4.93 | 97,070 | Form 4 |
| 30 June 2026 | Paulson John | Director | Grant or award | +12,677 | $4.93 | 430,242 | Form 4 |
| 30 June 2026 | Wechsler Amy B | Director | Grant or award | +1,394 | $4.93 | 314,979 | Form 4 |
| 22 May 2026 | Garcia Christian A | Director | Grant or award | +45,871 | — | 135,578 | Form 4 |
| 22 May 2026 | Goettler Michael | Director | Grant or award | +45,871 | — | 76,020 | Form 4 |
| 22 May 2026 | Kavanagh Sarah B | Director | Grant or award | +45,871 | — | 282,230 | Form 4 |
| 22 May 2026 | Lee Frank D. | Director | Grant or award | +45,871 | — | 95,210 | Form 4 |
| 22 May 2026 | Leung Sandra | Director | Grant or award | +45,871 | — | 90,225 | Form 4 |
| 22 May 2026 | Paulson John | Director | Grant or award | +45,871 | — | 417,565 | Form 4 |
| 22 May 2026 | Power Robert N | Director | Grant or award | +45,871 | — | 300,594 | Form 4 |
| 22 May 2026 | Roberts Eiry | Director | Grant or award | +45,871 | — | 45,871 | Form 4 |
| 22 May 2026 | Wechsler Amy B | Director | Grant or award | +45,871 | — | 313,585 | Form 4 |
| 19 May 2026 | Lee Frank D. | Director | Open-market sale, 10b5-1 plan | −24,456 | $5.43 | 49,339 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Bausch Health Companies page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.